Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood blood.2024025366.

https://doi.org/10.1182/blood.2024025366

Published: 2024

Includes: Supplemental data

Journal Articles

Newer insights on how to TEC down T-ALL

Swaminathan P. Iyer

Blood (2023) 141 (5): 444–445.

https://doi.org/10.1182/blood.2022018004

Published: 2023

Journal Articles

Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution

Chijioke Nze, Clark R Andersen, Amy Ayers, Jason Westin, Michael L. Wang, Swaminathan P. Iyer, Sairah Ahmed, Chelsea C. Pinnix, Francisco Vega, Lorna McNeil, Lynne Nguyen, Loretta J. Nastoupil, Christopher R. Flowers

Blood (2022) 140 (Supplement 1): 7943–7945.

https://doi.org/10.1182/blood-2022-165451

Published: 2022

Journal Articles

Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3598–3600.

https://doi.org/10.1182/blood-2022-162806

Published: 2022

Journal Articles

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Hans C. Lee, Gregory P. Kaufman, Lei Feng, Astrid Murga, Ralph J. Johnson, Donna M. Weber, Sheeba K Thomas, Qaiser Bashir, Muzaffar H Qazilbash, Swaminathan P. Iyer, Krina Patel, Melody R. Becnel, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4428–4430.

https://doi.org/10.1182/blood-2022-167555

Published: 2022

Journal Articles

Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy

Andrew Jallouk, Lei Feng, Mansoor Noorani, Kaberi Das, Raphael E Steiner, Loretta J. Nastoupil, Misha Hawkins, Ranjit Nair, Jason Westin, Luis Fayad, Dai Chihara, Luis Enrique Malpica Castillo, Swaminathan P. Iyer, Sairah Ahmed, Elizabeth J Shpall, Partow Kebriaei, Sattva S. Neelapu, Paolo Strati

Blood (2022) 140 (Supplement 1): 10424–10426.

https://doi.org/10.1182/blood-2022-166783

Published: 2022

Journal Articles

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Blood (2022) 140 (Supplement 1): 8326–8328.

https://doi.org/10.1182/blood-2022-170790

Published: 2022

Journal Articles

Cytomegalovirus (CMV) Reactivation within in the First Year after Chimeric Antigen Receptor (CAR) T Cell Therapy: Experience from the First Two Years at a Major Cancer Center

Fareed Khawaja, Rishab Prakash, Joseph Sassine, Guy Handley, Tracy VanWieren, Georgios Angelidakis, Swaminathan P. Iyer, Jeremy L. Ramdial, Sairah Ahmed, Yago Nieto, Amy Spallone, Ella J. Ariza-Heredia, Roy Chemaly

Blood (2022) 140 (Supplement 1): 7533–7535.

https://doi.org/10.1182/blood-2022-167908

Published: 2022

Journal Articles

Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

Blood (2022) 140 (Supplement 1): 9431–9433.

https://doi.org/10.1182/blood-2022-170921

Published: 2022

Journal Articles

High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

Blood (2022) 140 (Supplement 1): 1183–1184.

https://doi.org/10.1182/blood-2022-156121

Published: 2022

Journal Articles

Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin

Alexandra Elias, Rishab Prakash, Loretta J. Nastoupil, Nathan H. Fowler, Sairah Ahmed, Ranjit Nair, Luis Enrique Malpica Castillo, Bouthaina S. Dabaja, Jie Xu, Jeffrey Medeiros, John Stewart, Wei Wang, Chelsea C. Pinnix, Kelly Hunt, Mark W Clemens, Roberto N. Miranda, Swaminathan P. Iyer

Blood (2022) 140 (Supplement 1): 3721–3723.

https://doi.org/10.1182/blood-2022-170845

Published: 2022

Journal Articles

Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis

Blood (2022) 140 (Supplement 1): 2313–2315.

https://doi.org/10.1182/blood-2022-168983

Published: 2022

Journal Articles

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Blood (2022) 140 (5): 504–515.

https://doi.org/10.1182/blood.2022015601

Published: 2022

Includes: Supplemental data

Journal Articles

A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 38.

https://doi.org/10.1182/blood-2021-148314

Published: 2021

Journal Articles

No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis

Pamela Allen, Subir Goyal, Irl Brian Greenwell, Jane Scribner, Sunil Rangarajan, Amitkumar Mehta, Colin Burke O'Leary, Tim Niyogusaba, Auris Huen, Jeffrey M. Switchenko, Erica Shantha Tarabadkar, Amy Ayers, Shalini Krishnasamy, Pierluigi Porcu, Tarsheen Sethi, Swaminathan P Iyer, Mary Jo Lechowicz

Blood (2021) 138 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2021-151911

Published: 2021

Journal Articles

Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion

Blood (2021) 138 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2021-145503

Published: 2021

Journal Articles

Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy

Ajlan Al Zaki, Jason R. Westin, Grace Watson, Lei Feng, Sairah Ahmed, Haleigh Mistry, Loretta Nastoupil, Misha Hawkins, Ranjit Nair, Swaminathan P Iyer, Hun Lee, Raphael E Steiner, Christopher R. Flowers, Elizabeth J. Shpall, Partow Kebriaei, Sattva S. Neelapu, Paolo Strati

Blood (2021) 138 (Supplement 1): 3870.

https://doi.org/10.1182/blood-2021-146023

Published: 2021

Journal Articles

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, Jeffrey A. Zonder, Dahlia Sano, Michael Maris, Alexander Lesokhin, Gottfried von Keudell, Catherine Lai, Rod Ramchandren, Tina Catalano, Gloria H. Y. Lin, Bob Uger, Penka S. Petrova, Naomi Molloy, Ingmar Bruns, Swaminathan P Iyer

Blood (2021) 138 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2021-153683

Published: 2021

Journal Articles

Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

Swaminathan P Iyer, Auris Huen, Weiyun Z. Ai, Deepa Jagadeesh, Mary Jo Lechowicz, Craig Okada, Tatyana A. Feldman, Suchitra Sundaram, Juan Pablo Alderuccio, Nishitha Reddy, Don Stevens, Timothy M. Kuzel, Ann Mohrbacher, Kasi Viswanath Routhu, Prajak Barde, Ajit Mohanchandran Nair, Brad M. Haverkos

Blood (2021) 138 (Supplement 1): 1365.

https://doi.org/10.1182/blood-2021-145851

Published: 2021

Journal Articles

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, Kerry J. Savage, Tim Illidge, Swaminathan P Iyer, Ranjana Advani, Andrei R Shustov, Nancy L. Bartlett, Barbara Pro, Eric D Jacobsen, Raphael Koch, Domingo Domenech Eva, Michelle A. Fanale, Keenan Fenton, Frank Campana, Cassie Dong, Lorenz Truemper

Blood (2021) 138 (Supplement 1): 135.

https://doi.org/10.1182/blood-2021-145124

Published: 2021

NARROW

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Newer insights on how to TEC down T-ALL

Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution

Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Cytomegalovirus (CMV) Reactivation within in the First Year after Chimeric Antigen Receptor (CAR) T Cell Therapy: Experience from the First Two Years at a Major Cancer Center

Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin

Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis

Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion

Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only